Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Biopharma and life sciences companies from across the globe provide updates on their pipeline and business.
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
They expect to share the complete findings with regulators in the upcoming months and make a final decision on whether to continue the clinical trial.
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
AMO Pharma, a British biopharmaceutical company, is targeting a pathway most often associated with cancer to treat people with genetic encephalopathy.
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
While it may be quicker than developing a vaccine, finding the right drugs to treat the disease will still be tricky.
The culling of one-fourth of its employees is expected to save the company approximately $125 million through the end of 2021.
PRESS RELEASES